3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
37
Paclitaxel
18
Cisplatin
18
Carboplatin
14
Nivolumab
13
Hyperthermic Intraperitoneal Chemotherapy
13
Docetaxel
11
Cyclophosphamide
11
Oxaliplatin
9
Irinotecan
9
Fluorouracil
9
atezolizumab
8
Trastuzumab
8
Leucovorin
8
Bevacizumab
8
fludarabine
7
Magnetic Resonance Spectroscopy
7
Specimen Handling
6
Ipilimumab
6
Gemcitabine
6
Mitomycin
5
Cytoreduction Surgical Procedures
5
Capecitabine
5
durvalumab
4
cemiplimab
4
aldesleukin
4
Taxes
4
Psychiatric Rehabilitation
4
Platinum
4
Drug Therapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled